|
|
Investor Relations
Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon's lead product candidate is Silenor® (doxepin) for the treatment of insomnia.
Latest News
Jul 29, 2010
Somaxon Pharmaceuticals to Present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference (pdf)
Jul 21, 2010
Somaxon Pharmaceuticals Announces Acceptance of Phase 3 Clinical Trial Data for Phase 3 Clinical Trial Data for Publication in Sleep and Sleep Medicine (pdf)
Webcasts
|
| Stock Quote |
SOMX(Common Stock)
Last Trade $3.69
Change  0.05
Exchange NASDAQ
Volume 1,163,400
07/30/10 4:00 PM ET
Minimum 20 Minute Delay.
Refresh Quote.
|
Annual Reports
|
